NEW YORK (GenomeWeb News) – Enzo Biochem will seek CLIA waivers for GeneNews' colorectal cancer test in New York and New Jersey and market the test in those states, under an agreement announced by the firms today.

Enzo plans to validate and seek approval in New York, New Jersey, and under CLIA requirements for the ColonSentry blood-based test for colorectal cancer risk. It also intends to market and secure third-party reimbursement for the test. Enzo said it hopes to make the test available in the second half of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.